Kura Oncology posts corporate presentation on KOMZIFTI launch, ziftomenib pipeline strategy
KURA•Cash position and collaboration funding
- Cash and investments of USD 519 million as of June 30, 2026; USD 180 million of anticipated collaboration payments.
- Kyowa Kirin collaboration: 50/50 U.S. co-development and co-promotion; Kura books 100% U.S. sales.
- Funding expected to support the ziftomenib AML program through topline results from Phase 3 KOMET-017, anticipated in 2028.
KOMZIFTI launch and early revenue momentum
Kura highlighted KOMZIFTI (ziftomenib) for adult relapsed or refractory NPM1-mutated AML, citing early launch momentum.
- 2Q 2026 KOMZIFTI net product revenue of USD 9.1 million, up 57% from 1Q; about 115 new patient starts.
